Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD

In the N-MOmentum trial, the risk of an adjudicated neuromyelitis optica spectrum disorder (NMOSD) attack was significantly reduced with inebilizumab compared with placebo. To demonstrate the robustness of this finding, using pre-specified sensitivity and subgroup analyses. N-MOmentum is a prospecti...

Celý popis

Podrobná bibliografie

Vydáno v:	Multiple sclerosis Ročník 27; číslo 13; s. 2052
Hlavní autoři:	Cree, Bruce Ac, Bennett, Jeffrey L, Kim, Ho Jin, Weinshenker, Brian G, Pittock, Sean J, Wingerchuk, Dean, Fujihara, Kazuo, Paul, Friedemann, Cutter, Gary R, Marignier, Romain, Green, Ari J, Aktas, Orhan, Hartung, Hans-Peter, Williams, Ian M, Drappa, Jorn, She, Dewei, Cimbora, Daniel, Rees, William, Ratchford, John N, Katz, Eliezer
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.11.2021
Témata:	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Aquaporin 4 Humans Neuromyelitis Optica - drug therapy Prospective Studies clinical trial patient demographics Attack risk neuromyelitis optica spectrum disorder neuromyelitis optica sensitivity analyses Devic’s disease inebilizumab
ISSN:	1477-0970, 1477-0970
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!